Sector: University & Research Institutions

Latest content

MPEG LA chief calls on rights owners to make CRISPR patent pool a reality

Larry Horn speaks exclusively to IAM about the future of biotech joint licensing programmes

25 March 2022

JPO presses case for grace period harmony as trade deals bring issue to the fore

The grace period gap between major jurisdictions has recently been thrust into the spotlight. The JPO is one stakeholder pushing for major players to seize momentum and work towards harmonisation

23 March 2022

Sanofi scores $300 million in unusual royalty deal

Deal announced by French pharma giant this week is highly distinctive, but also reflects several recent trends in the booming drug revenue market

17 March 2022

Breakthrough in TRIPS covid waiver negotiations – here’s what you need to know

There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation

16 March 2022

Vaccine hub leader welcomes new Moderna patent pledge, but calls for collaboration

Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment

14 March 2022

Medical device maker is latest to tap secondary market for wireless patents

A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs

08 March 2022

Platform technology owners demand a chunk of Moderna’s covid-19 revenues

Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator

07 March 2022

Broad Institute’s big US CRISPR patent win does little to clear path for Cas9 licensees

As the US and European gene-editing IP landscapes drift further apart, therapeutics companies face difficult freedom-to-operate quandaries

03 March 2022

More is being done than ever before to monetise neglected pharma IP

Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents

22 February 2022

Lack of mRNA tech transfer “a blessing in disguise” for WHO vaccine team, says Afrigen boss

Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine

10 February 2022

Unlock unlimited access to all IAM content